ClinicalTrials.Veeva

Menu

A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG

M

Mati Therapeutics

Status and phase

Completed
Phase 2

Conditions

Open-Angle Glaucoma
Ocular Hypertension

Treatments

Drug: Xalatan
Drug: Latanoprost Punctal Plug Delivery System

Study type

Interventional

Funder types

Industry

Identifiers

NCT01037036
PPL GLAU 08

Details and patient eligibility

About

The objective of this study is to investigate how the intraocular pressure (IOP)-lowering effect of the L-PPDS is altered by adjunctive Xalatan therapy.

Enrollment

15 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Over 18 years
  • Diagnosed with bilateral Open-Angle Glaucoma or Ocular Hypertension
  • Currently on prostaglandin therapy

Exclusion criteria

  • Uncontrolled medical conditions
  • Subjects who wear contact lenses
  • Subjects requiring chronic topical artificial tears, lubricants, and /or - requiring any other chronic topical medications

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

15 participants in 1 patient group

Latanoprost Punctal Plug Delivery System followed by Xalatan
Experimental group
Description:
Subjects will have the Latanoprost Punctal Plug Delivery System placed for 4 week or until loss of efficacy. After removal of the Latanoprost Punctal Plug Delivery system, subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study.
Treatment:
Drug: Xalatan
Drug: Latanoprost Punctal Plug Delivery System

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems